Biohaven Stock Catapults On A Surprise FDA Move Why It Might Not Be Done Running
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole.
ETH-5.22%
BTC-3.91%
SOL-4.25%
XRP-4.64%
USDC+0.04%
DOGE-5.77%
SUI-6.63%
HYPE-4.91%ETH-5.22%BTC-3.91%SOL-4.25%XRP-4.64%USDC+0.04%DOGE-5.77%SUI-6.63%HYPE-4.91%ETH-5.22%BTC-3.91%SOL-4.25%XRP-4.64%USDC+0.04%DOGE-5.77%SUI-6.63%HYPE-4.91%ETH-5.22%BTC-3.91%SOL-4.25%XRP-4.64%USDC+0.04%DOGE-5.77%SUI-6.63%HYPE-4.91%
